{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:02:04Z","timestamp":1777420924182,"version":"3.51.4"},"reference-count":77,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T00:00:00Z","timestamp":1416441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2015,2]]},"abstract":"<jats:p>Objective: To describe the current Ebola virus epidemic and the potential options for treatment and prevention of Ebola virus disease. Data Sources: A PubMed literature search (1976 through October 20, 2014) was conducted using the search term Ebola. Study Selection and Data Extraction: Animal and human studies published in English were selected. Studies published within the past 5 years were the primary focus of this review. Data Synthesis: The current Ebola virus epidemic has primarily been contained in West Africa though it has subsequently spread to other areas, including the United States. The first patient in the United States infected with Ebola virus was diagnosed, treated, and expired in Texas. Two nurses caring for this patient also were diagnosed with Ebola virus and have been successfully treated. Treatment options for patients infected with Ebola virus are limited. Supportive therapy is centered on fluid resuscitation, electrolyte imbalance correction, treating complicating infections, and preventing complications of shock. Experimental therapies (ZMapp, brincidofovir, TKM-Ebola, and favipiravir) have been used during this current outbreak. Several medications such as amiodarone, chloroquine, and clomiphene may prevent the transmission of or treat Ebola virus. Different vaccine therapies are also in early-stage development. One of the vaccine strategies using recombinant vesicular stomatitis virus as a delivery vector has demonstrated efficacy when used for preexposure and postexposure prophylaxis. Conclusion: Ebola virus is highly virulent and fatal, and treatment options are limited. Several experimental and existing therapies may be options for preventing and treating Ebola virus disease.<\/jats:p>","DOI":"10.1177\/1060028014561227","type":"journal-article","created":{"date-parts":[[2014,11,20]],"date-time":"2014-11-20T23:00:12Z","timestamp":1416524412000},"page":"196-206","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":85,"title":["Potential and Emerging Treatment Options for Ebola Virus Disease"],"prefix":"10.1177","volume":"49","author":[{"given":"Bryan M.","family":"Bishop","sequence":"first","affiliation":[{"name":"St Rita\u2019s Medical Center, Lima, OH, USA"},{"name":"Rudolph H. Raabe College of Pharmacy at Ohio Northern University, Ada, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2014,11,20]]},"reference":[{"key":"bibr1-1060028014561227","first-page":"875","volume-title":"Clinical Virology","author":"Bray M","year":"2002"},{"key":"bibr2-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411100"},{"key":"bibr3-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2005.05.001"},{"key":"bibr4-1060028014561227","unstructured":"World Health Organization. What we know about transmission of the Ebola virus among humans. http:\/\/www.who.int\/media-centre\/news\/ebola\/06-october-2014\/en\/. Accessed October 21, 2014."},{"key":"bibr5-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-010-0791-0"},{"key":"bibr6-1060028014561227","first-page":"1531","volume":"109","author":"Piercy TJ","year":"2010","journal-title":"J Appl Microbiol"},{"key":"bibr7-1060028014561227","unstructured":"World Health Organization. Barriers to rapid containment of the Ebola outbreak. http:\/\/www.who.int\/csr\/disease\/ebola\/overview-august-2014\/en\/. Accessed October 21, 2014."},{"key":"bibr8-1060028014561227","unstructured":"The Centers for Disease Control and Prevention. Ebola virus disease information for clinicians in U.S. healthcare settings. http:\/\/www.cdc.gov\/vhf\/ebola\/hcp\/clinician-information-us-healthcare-settings.html. Accessed October 21, 2014."},{"key":"bibr9-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1086\/514308"},{"key":"bibr10-1060028014561227","unstructured":"The Centers for Disease Control and Prevention. Interim guidance for specimen collection, transport, testing, and submission for persons under investigation for Ebola virus disease in the United States. http:\/\/www.cdc.gov\/vhf\/ebola\/hcp\/interim-guidance-specimen-collection-submission-patients-suspected-infection-ebola.html. Accessed October 21, 2014."},{"key":"bibr11-1060028014561227","volume-title":"Clinical Management of Patients With Viral Hemorrhagic Fever: A Pocket-Guide for the Frontline Health Worker","author":"World Health Organization","year":"2014"},{"key":"bibr12-1060028014561227","volume-title":"WHO Consultation on Potential Ebola Therapies and Vaccines: Background Document for Participants","author":"World Health Organization","year":"2014"},{"key":"bibr13-1060028014561227","unstructured":"Pollack A. Second drug is allowed for treatment of Ebola. http:\/\/www.nytimes.com\/2014\/08\/08\/health\/second-experimental-drug-allowed-for-treating-ebola.html. Accessed October 21, 2014."},{"key":"bibr14-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006608"},{"key":"bibr15-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1038\/nature13777"},{"key":"bibr16-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5488"},{"key":"bibr17-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5539"},{"key":"bibr18-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1086\/514298"},{"key":"bibr19-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61693-7"},{"key":"bibr20-1060028014561227","unstructured":"Besser R. Why Dr. Kent Brantly couldn\u2019t donate blood to Thomas Eric Duncan. http:\/\/abcnews.go.com\/Health\/dr-kent-brantly-donate-blood-thomas-eric-duncan\/story?id=26226388. Accessed October 21, 2014."},{"key":"bibr21-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1300266"},{"key":"bibr22-1060028014561227","unstructured":"Christensen J. Ebola drugs are in the works. http:\/\/www.cnn.com\/2014\/10\/06\/health\/ebola-drugs-in-the-works\/. Access-ed November 1, 2014."},{"key":"bibr23-1060028014561227","unstructured":"Chimerix Inc. Chimerix announces emergency investigational new drug applications for brincidofovir authorized by FDA for patients with Ebola virus disease. http:\/\/ir.chimerix.com\/releasedetail.cfm?releaseid=874647. Accessed October 21, 2014."},{"key":"bibr24-1060028014561227","doi-asserted-by":"publisher","DOI":"10.3390\/v2122740"},{"key":"bibr25-1060028014561227","unstructured":"Chimerix. An open-label, multicenter study of the safety and anti-viral activity of brincidofovir (BCV, CMX001) for Ebola virus disease. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT0227-1347. Accessed November 10, 2014."},{"key":"bibr26-1060028014561227","unstructured":"Wiley F. The 3 drug classes for experimental Ebola treatment. http:\/\/www.pharmacytimes.com\/contributor\/frieda-wiley\/2014\/10\/the-3-drug-classes-for-experimental-ebola-treatment. Acces-sed November 2, 2014."},{"key":"bibr27-1060028014561227","unstructured":"Caplan A. New drug brincidofovir may be useful in treating Ebola: expert. http:\/\/www.nydailynews.com\/life-style\/health\/new-drug-brincidofovir-treating-ebola-expert-article-1.19866-81. Accessed November 2, 2014."},{"key":"bibr28-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa-1303688"},{"key":"bibr29-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05983-11"},{"key":"bibr30-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00649-13"},{"key":"bibr31-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003725"},{"key":"bibr32-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00356-07"},{"key":"bibr33-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00886-13"},{"key":"bibr34-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.02.014"},{"key":"bibr35-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2014.01.012"},{"key":"bibr36-1060028014561227","unstructured":"Trompiz G. First French Ebola patient leaves hospital. http:\/\/www.reuters.com\/article\/2014\/10\/04\/us-health-ebola-france-id-USKCN0HT0D720141004. Accessed October 21, 2014."},{"key":"bibr37-1060028014561227","unstructured":"Koons C, Matsuyama K, Langreth R. Ebola drug from Japan may emerge among key candidates. http:\/\/www.bloomberg.com\/news\/2014-08-07\/ebola-drug-from-japan-may-emerge-among-key-candidates.html. Accessed October 17, 2014."},{"key":"bibr38-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g5103"},{"key":"bibr39-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60357-1"},{"key":"bibr40-1060028014561227","doi-asserted-by":"publisher","DOI":"10.3390\/v4112806"},{"key":"bibr41-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2014.07.008"},{"key":"bibr42-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03442-14"},{"key":"bibr43-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1038\/nature13027"},{"key":"bibr44-1060028014561227","unstructured":"Beaubien J. A Liberian doctor comes up with his own Ebola regimen. http:\/\/www.npr.org\/blogs\/goatsandsoda\/2014\/10\/10\/355164328\/a-liberian-doctor-comes-up-with-his-own-ebola-re-gimen. Accessed November 2, 2014."},{"key":"bibr45-1060028014561227","unstructured":"Fauci AS, Collins FS. NIH Ebola update: working toward treatments and vaccines. http:\/\/directorsblog.nih.gov\/2014\/10\/14\/nih-ebola-update-working-toward-treatments-and-vaccines\/. Accessed November 2, 2014."},{"key":"bibr46-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060579"},{"key":"bibr47-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1089\/vbz.2008.0049"},{"key":"bibr48-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0000785"},{"key":"bibr49-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2764"},{"key":"bibr50-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63592-4"},{"key":"bibr51-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005471"},{"key":"bibr52-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku091"},{"key":"bibr53-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1186\/cc11895"},{"key":"bibr54-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-08-0720"},{"key":"bibr55-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu474"},{"key":"bibr56-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1186\/cc13828"},{"key":"bibr57-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082775"},{"key":"bibr58-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3418-1"},{"key":"bibr59-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1159\/0003-21892"},{"key":"bibr60-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-13-203"},{"key":"bibr61-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3702"},{"key":"bibr62-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00561-09"},{"key":"bibr63-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1412166"},{"key":"bibr64-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1038\/nm1258"},{"key":"bibr65-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005547"},{"key":"bibr66-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/j.vac-cine.2008.09.082"},{"key":"bibr67-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61371-4"},{"key":"bibr68-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030002"},{"key":"bibr69-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201408-1514CP"},{"key":"bibr70-1060028014561227","volume-title":"Paper presented at: IDWeek","author":"Ribner BS"},{"key":"bibr71-1060028014561227","doi-asserted-by":"publisher","DOI":"10.3390\/v4091668"},{"key":"bibr72-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60667-8"},{"key":"bibr73-1060028014561227","doi-asserted-by":"publisher","DOI":"10.1086\/596711"},{"key":"bibr74-1060028014561227","unstructured":"Infectious Diseases Society of America. IDSA Ebola guidance. http:\/\/www.idsociety.org\/2014_ebola\/. Accessed November 2, 2014."},{"key":"bibr75-1060028014561227","unstructured":"Canadian Critical Care Society, Canadian Association of Emergency Physicians, Association of Medical Microbiology and Infectious Diseases Canada. Ebola clinical care guidelines: a guide for clinicians in Canada. http:\/\/www.healthycanadians.gc.ca\/diseases-conditions-maladies-affections\/disease-maladie\/ebola\/professionals-professionnels\/index-eng.php. Accessed November 11, 2014."},{"key":"bibr76-1060028014561227","volume-title":"Filovirus Haemorrhagic Fever Guideline","author":"M\u00e9decins Sans Fronti\u00e8res","year":"2008"},{"key":"bibr77-1060028014561227","volume-title":"Management of Hazard Group 4 Viral Haemorrhagic Fevers and Similar Human Infectious Diseases of High Consequence","author":"Advisory Committee on Dangerous Pathogens","year":"2014"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014561227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1060028014561227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1060028014561227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:15:33Z","timestamp":1777374933000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1060028014561227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,20]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.1177\/1060028014561227"],"URL":"https:\/\/doi.org\/10.1177\/1060028014561227","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,20]]}}}